Veru Inc. (VERU) News
Filter VERU News Items
VERU News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
VERU News Highlights
- For VERU, its 30 day story count is now at 6.
- Over the past 25 days, the trend for VERU's stories per day has been choppy and unclear. It has oscillated between 1 and 2.
- The most mentioned tickers in articles about VERU are DRUG, ARDS and FL.
Latest VERU News From Around the Web
Below are the latest news stories about VERU INC that investors may wish to consider to help them evaluate VERU as an investment opportunity.
Veru Inc.'s (NASDAQ:VERU) recent 20% pullback adds to one-year year losses, institutional owners may take drastic measuresKey Insights Given the large stake in the stock by institutions, Veru's stock price might be vulnerable to their... |
UPDATE 1-Veru to proceed with late-stage study of COVID pill despite FDA snubDrug developer Veru Inc on Tuesday said it plans to proceed with a late-stage trial of its COVID-19 pill, weeks after the U.S. health regulator declined to authorize the oral drug to treat high-risk patients hospitalized with COVID-19. Veru plans to continue development of the oral drug, sabizabulin, in late-stage studies with high-risk hospitalized influenza patients and COVID-19 patients. Additionally, Veru will stop the development of two of its other cancer drug candidates - VERU-100 and zuclomiphene - which it was testing in mid-stage studies for various indications. |
Veru to Present at the Oppenheimer 33rd Annual Healthcare ConferenceMIAMI, FL., March 07, 2023 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a biopharmaceutical company focused on developing novel medicines for COVID-19 and other viral ARDS-related diseases and for oncology, today announced that Mitchell Steiner, M.D., Chairman, President and Chief Executive Officer of Veru, will present at the upcoming virtual Oppenheimer 33rd Annual Healthcare Conference on Tuesday, March 14, 2023 at 12 pm ET. In this presentation, Veru's CEO plans to share the Company's curre |
First Solar (FSLR) Stock Pops on Analyst UpgradeFirst Solar (FSLR) stock rose on Friday after the solar power company got an upgrade and increased price target from UBS. |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on FridayWe're starting off Friday morning with a breakdown of the biggest pre-market stock movers traders need to keep an eye on! |
Why Is Lucira Health (LHDX) Stock Down 14% Today?Lucira Health (LHDX) stock is falling on Friday after the company's shares have seen extreme volatility throughout the week. |
Why Is Veru (VERU) Stock Down 37% Today?Veru (VERU) stock is taking a beating on Friday after the FDA denied the company's request for EUA for its Covid-19 treatment. |
Why Veru Stock Is Crashing Today?The FDA declined to grant Veru Inc's (NASDAQ: VERU) request for Emergency Use Authorization (EUA) for sabizabulin to treat hospitalized adult patients with moderate to severe COVID-19 who are at high risk for Acute Respiratory Distress Syndrome (ARDS). Separately, the FDA also commented on the company's proposed confirmatory Phase 3 study protocol for hospitalized moderate to severe COVID-19 patients at risk for ARDS and death that could support a new EUA authorization and/or NDA approval. Also |
Veru stock plummets toward 2 1/2-year low after FDA denies EUA request for COVID-19 treatmentShare of Veru Inc. (VERU) plunged 31.0% toward a 2 1/2-year low in premarket Friday, after the U.S. Food and Drug Administration turned down the biopharmaceutical company’s request for Emergency Use Authorization (EUA) for sabizabulin, its treatment for hospitalized patients with COVID-19 who are at high risk for Acute Respiratory Distress Syndrome (ARDS). The company said that although the FDA declined the EUA request, “the FDA remains committed to working with the company for the development of sabizabulin.” Separately, the company expects to soon provide details of the timing and design of a proposed confirmatory Phase 3 study it submitted, that could support a new EUA authorization. |
Veru Provides FDA Update on Request for Emergency Use Authorization for Sabizabulin for Hospitalized COVID-19 Patients at High Risk for ARDSMIAMI, FL, March 02, 2023 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a biopharmaceutical company focused on developing novel medicines for COVID-19 and other viral ARDS-related diseases and for oncology, today announced that the U.S. Food and Drug Administration (FDA) has declined to grant at this time the Company’s request for Emergency Use Authorization (EUA) for sabizabulin, Veru’s novel microtubule disruptor, to treat hospitalized adult patients with moderate to severe COVID-19 who are at |